NCT04466241View on ClinicalTrials.gov

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2021

Conditions
COVID-19COVID-19 Drug TreatmentSevere Acute Respiratory Syndrome Coronavirus 2
Interventions
DRUG

Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet

2 tablets morning and evening from Day 1 to Day 10

DRUG

Telmisartan 40Mg Oral Tablet

1 tablet daily from Day 1 to Day 10

DRUG

Atorvastatin 20 Mg Oral Tablet

1 tablet daily from Day 1 to Day 10

Trial Locations (2)

01 BP V3

Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan

21 BP 632

Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan

All Listed Sponsors
collaborator

University of Bordeaux

OTHER

collaborator

PACCI Program

OTHER

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT04466241 - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial | Biotech Hunter | Biotech Hunter